Bioventus Announces Launch of Initial Public Offering
February 04 2021 - 08:10AM
Business Wire
Bioventus Inc. ("Bioventus" or the “Company”), today announced
that it has commenced the initial public offering of its Class A
common stock. Bioventus is offering 7,350,000 shares of its Class A
common stock. The initial public offering price is expected to be
between $16.00 and $18.00 per share. Bioventus expects to grant the
underwriters a 30-day option to purchase up to an additional
1,102,500 shares of its common stock at the initial public offering
price to cover over-allotments. The shares are expected to trade on
the Nasdaq Global Select Market under the ticker symbol “BVS.”
Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and
Goldman Sachs & Co. LLC are serving as joint lead book-running
managers and as representatives of the underwriters for the
proposed offering. Canaccord Genuity LLC is acting as lead manager
for the offering.
The offering will be made only by means of a prospectus. A copy
of the preliminary prospectus relating to the proposed offering may
be obtained from any of the following sources:
- Morgan Stanley & Co. LLC, Attention: Prospectus Department,
180 Varick Street, 2nd Floor, New York, NY 10014 or by email at
prospectus@morganstanley.com;
- J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at 1-866-803-9204 or by email at
prospectus-eq_fi@jpmchase.com; or
- Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY 10282, by telephone at (866)
471-2526, or by email at prospectus-ny@ny.email.gs.com.
A registration statement on Form S-1 relating to these
securities has been filed with the Securities and Exchange
Commission but has not yet become effective. These securities may
not be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Bioventus
Bioventus delivers clinically proven, cost-effective products
that help people heal quickly and safely. Its mission is to make a
difference by helping patients resume and enjoy active lives. The
Innovations For Active Healing from Bioventus include offerings for
osteoarthritis, surgical and non-surgical bone healing. Built on a
commitment to high quality standards, evidence-based medicine and
strong ethical behavior, Bioventus is a trusted partner for
physicians worldwide.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210204005648/en/
Investors Bioventus Investor Relations
investor.relations@bioventus.com
Media Thomas Hill thomas.hill@bioventusglobal.com
BroadVision (NASDAQ:BVSN)
Historical Stock Chart
From Feb 2024 to Mar 2024
BroadVision (NASDAQ:BVSN)
Historical Stock Chart
From Mar 2023 to Mar 2024